Acciones inmunofarmacológicas de las inmunoglobulinas intravenosas.

Immune-pharmacological actions of Intravenous Immunoglobulins.

Amaury Noda1, Boris Rodríguez1, Arturo Vidal1, Armando Cádiz2.

1. Hospital Pediátrico Eliseo Noel Caamaño. Matanzas, Cuba.

RESUMEN

Se ha recorrido un largo camino en la comprensión de los mecanismos de acción relativos a la infusión de
preparados de inmunoglobulinas intravenosas desde los días donde un crudo de fracción II de Cohn obtenido de
plasma humano fue administrado intramuscularmente a pacientes aquejados de agammaglobulinemia de
Brutton, hasta nuestros días. Debemos hacer una distinción entre los mecanismos de acción al nivel del
patógeno que provoca la enfermedad, de aquellos al nivel de una enfermedad dada provocada por la reacción
del huésped contra el patógeno. El efecto de supresión de las inmunoglobulinas intravenosas en las respuestas ]]> autoinmunes abre nuevas perspectivas terapéuticas y permite un nuevo acercamiento a la comprensión de los
mecanismos básicos que explican la autoinmunidad patológica.

Palabras claves: Inmunoglobulinas intravenosas, mecanismos de acción, autoinmunidad, inflamación, acciones
farmacológicas.

ABSTRACT

We have come a long way in the understanding of the mechanisms of action occurring upon infusion of intravenous immunoglobulin since the days when crude Cohn fraction II of human plasma was administered intramuscularly to patients suffering from Brutton’s agammaglobulinemia, up to modern times. A distinction should be made between mechanisms of action at the level of the pathogen causing the disease and those at the level of a given disease caused by the reaction of the host against the pathogen. The suppresive effect of intravenous immunoglobulins on autoinmune responses opens novel therapeutic prospects and provides a new approach for understanding the basic mechanisms that explain pathological autoinmunity.

Keywords: Intravenous immunoglobulins, mechanisms of action, autoimmunity, inflammation, pharmacological effects.

texto completo en pdf

REFERENCIAS ]]>

1. Coutinho A. The network theory: 21 years later. Scand Immunol 1995;42:3-8.

2. Dietrich G, Kaveri SV, Kazatchkine MD. Modulation of autoimmunity by intravenous immunoglobulin through interaction with the function of the immune idiotypic network. Clin Immunol Immunopathol 1992;62:S73-S81.

3. Foster BJ, Duffy CM, Sharma AK. Systemic juvenile Rheumatoide Arthrytis Complicated by two different renal lesions. Pediatric Nephrol. 1998;12:113-116.

4. Dalakas MC: Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic disease. Neurology 1998;51(Suppl 5): S2-S8.

5. Kotzin BL, Leung DY, Kappler J, et al. Toxic shock syndrome toxin-secreted staphylococcus aureaus in Kawasaky Syndrome. Lancet 1993;342:1385-1388.

6. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-Cell receptor variable regions V Beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992; 89:40-66-4070.

7. Takei S, Arora YK, Walker SM. Intravenous Immunoglobulin contain specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993; 91:602-607.

8. Kato H: Kawasaki disease. Proceedings of the 5^th International Kawasaki disease Symposium, Fukuoka, Japan. Amsterdam:Elsevier. 1995.

9. Fischer P, Uttenreuther MM, Naoe SH, et al: Kawasaki disease: Update undiagnosis, treatment, and still controversial etiology. Pediatr. Haematol and Oncology 1996,13:487-501.

10. Farantino MD, Madden RM, Fennewald DL, et al: Treatment of acute immune thrombocytopenia purpure with anti D immunoglobulin pooled immunoglobulin. J Pediatr 1999;134(1):21-26.

11. George JN, Woolf SH, Raskob GG, et al. Idiopatic thrombocytopenia purpura: a pratice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 40:3-40.

12. Domen RE: An overview of immnune hemolytic anemias. Cleveland Clinic Journal of Medicine 1998; 65:89-99.

13. Basta M, Dalakas MC: High dose intravenous immnugolobulin exerts it beneficial effect in patiens with dermatomyositis in blockin endomisial deposition of activated complement fragments. J Clin Invest 1994; 94:1729-1735.

14. Basta M: Modulation of complement _mediated immune damage by intravenous immunoglobulin. Clin Exp Immunol 1996; 196:7-12.

15. Rieben R, Roos A, Muizert Y, et al. Immunoglobulin Menriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflamation. Blood 1999; 93:9442-52.

16. Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins and chemokines in the progression of the rheumatoid arthritis. Seminars in Arthritis and Rheumatism.1996; 26:526-538.

17. Barret KE. Cytokines: sources, receptors and signalling. Bailliere's Clinical Gastroenterology 1996;10:1-15.

18. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5-19.

19. Andersson J, Skanse N, Sphir U, et al: Intravenous Immunoglobulin affects cytokynes production in T lymphocytes and monocytes-macrophages. Clin Exp Immunol 1996;104:10-21.

20. Blasezy R, Westhoff N, Grosse-Wilde H: Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations . Lancet 1993;341:789-790.

21. Kekow J, Reinhol D, Papt, et al. Intravenous Immunoglobulins and transforming growth factor b. Lancet 1998; 351:184-185.

22. Archiron A, Gabbay U, Gilad, et al: Intravenous Immunoglobulin treatment in multiple sclerosis. Effect on relapses Neurolgy 1998; 50:398-402.

23. Van Engelson BGM, Miller DJ, Pavelkok D, et al. Promotion of remyelination by polyclonal immunoglobulin in theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychatry 1994; 57 (Supply):65-68.

24.Gabriel CM, Gregson NA, Redford EJ, et al. Human immunoglobulin ameliorates rat experimental allergic neuritis Brain 1997; 120:1533-54.